Full-Time
Field Service Engineer
Posted on 9/8/2025
Cooper Companies
201-500 employees
Global medical devices and vision care
No salary listed
Paris, France
In Person
Preferred Location: Paris or surrounding area; job is field-based with expected weekly traveling.
 Mechanical Engineering (1) |
|---|
- Diploma in engineering, technical or Certificate of Higher Education
- + 3 years of experience from a similar role. Medical or IVF is a plus.
- Experience from an international set-up
- Time management and planning skills
- Solution oriented with business understanding
- Structured and systematic approach
- Good diplomatic communication and collaboration skills
- Be able to navigate in a diverse landscape of clients
- Fluent France and strong English skills. Another language is a plus.
- Good interpersonal communication skills when relating to customers, peers, and management.
- Customer service-oriented mind
- Understanding this is not a 9-to-5 job
- Good understanding of CRM systems
- Good understanding of RMA processes
- Analytical ability to diagnose the repair needs of improperly functioning products
- Capability to handle multiple cases and work orders in a fast-paced environment whilst maintaining calm and organized.
- Ensure timely and effective service, repair and installation of products
- Support teammates and customers in France
- Optimize customer experience
- Advice and guide customers to better use and experience with our products
- Main responsibility will be to travel to labs/clinics around Europe, mainly France (and occasionally in the rest of the world) to service, repair and install mechanical, electronic and/or software related medical devices
- Maintain your tools and spares equipment to be in line with specification
- Assist other Field Service Engineers wherever possible to enable them to carry out their duties when necessary. This will include cross training and shadowing
- Participate in the equipment provision for workshops, conferences, and trade shows (setup and tear down) assuring care and maintenance of equipment and packaging
- Follow systems and procedures outlined by the company and comply with local legislation
- Assist with telephone technical support and when required, and gain an understanding of FLS-processes to cover FLS (Front line Support) duties when required
- Manage travel arrangements related to fieldwork with a focus on reducing downtime and travel related costs
Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.
Company Size
201-500
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
1958
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $1.02B, raising FY2026 guidance to $4.31B-$4.35B.
- Paul Keel joins board July 2026, adding Envista CEO expertise for operations scaling.
- 18 consecutive years of CooperVision contact lens market share gains through premium portfolio.
What critics are saying
- Alcon's Total30 lenses erode CooperVision's daily disposable share within 6-12 months.
- Japan hydrogel decline cuts Asia Pacific revenue 5-7% in 3-6 months.
- Cook Medical recaptures 10-15% CooperSurgical fertility share via hospital contracts in 12-18 months.
What makes Cooper Companies unique
- CooperVision leads with MyDay and MiSight premium contact lenses for astigmatism and myopia.
- CooperSurgical offers vertically integrated fertility genomics and women's health devices.
- Dual-segment model separates vision care from reproductive health for focused innovation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Performance Bonus
Health Insurance
401(k) Retirement Plan
Life Insurance
Wellness Program
Professional Development Budget
Company News
CooperCompanies appoints Paul Keel to its Board of Directors. GlobeNewswire | CooperCompanies Yesterday at 1:15pm PDT SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) - CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders." Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel's career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com. Forward-Looking Statements This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to the Company's efforts to enhance long-term shareholder value, plans, strategies, future actions, and other statements of which are other than statements of historical fact, are forward-looking. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Statements regarding future events and performance and contain words such as "expects" and similar words or phrases. A wide range of factors could materially affect future developments, including, but not limited to, uncertainties related to market conditions and other factors set forth in its other filings with the United States Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. These risks and uncertainties may cause actual future results or actions to be materially different than those expressed in such forward-looking statements. Oregon Capital Insider do not intend, or undertake any duty, to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
Cooper Companies has raised $120 million in a Series C round, valuing the healthcare company at $1.45 billion, as shares face recent pressure with declines of 9% over the past month and roughly 17% over three months. The company operates two main businesses: CooperVision, generating revenue of $2.79 billion from contact lenses, and CooperSurgical, contributing $1.36 billion from women's and family health products. Total annual revenue reached $4.15 billion with net income of $401.4 million. Recent analysis suggests the stock may be 24.1% undervalued at its current price of $69.66, with a fair value estimate of $91.80. Management projects approximately $2 billion in free cash flow over the next three years as capital expenditure cycles wind down.
CooperCompanies reported Q4 revenues of $1.02 billion, up 6.2% year on year, meeting analysts' expectations. The medical devices manufacturer, which focuses on vision care and women's health products, delivered an impressive beat on full-year earnings per share guidance, though organic revenue was in line with estimates. The company raised both earnings and free cash flow guidance following strong profitability and cash generation. Operating margins exceeded expectations due to synergies from last year's reorganisation. President and CEO Al White highlighted momentum from product launches, including the premium MyDay portfolio and early traction from MyDay MiSight. Across the medical devices and supplies sector, six tracked companies reported mixed Q4 results, with revenues collectively beating consensus estimates by 1.9%. Share prices have declined 9.5% on average since earnings announcements.
Cooper Companies, a California-based medical devices manufacturer, has declined 12.5% over the past 52 weeks, underperforming the Dow Jones Industrial Average's 13.2% gain during the same period. The company, valued at $13.9 billion, has fallen 20.9% from its December 2025 peak of $89.83. Shares dropped 2.2% on 5 March following mixed Q1 2026 results. Whilst revenue rose 6% year-over-year to $1 billion and adjusted earnings per share increased 20% to $1.10, both beating estimates, investors focussed on weak organic revenue growth and challenges in the Asia Pacific region. The stock has traded below its 200-day and 50-day moving averages since early March. Despite the decline, analysts maintain a "Moderate Buy" rating with a mean price target of $90.81, suggesting 27.8% upside potential.
Needham raised its price target on The Cooper Companies (NASDAQ: COO) to $101 from $99, maintaining a Buy rating. The firm cited solid first-quarter results, improving end markets and operating efficiencies supporting margin expansion. Barclays also increased its target to $103 from $98 with an Overweight rating, noting improving sequential growth in Vision and Surgical segments offsetting declines in older hydrogel products in Japan. Cooper Companies reported first-quarter non-GAAP earnings per share of $1.10, beating the $1.03 consensus estimate, with revenue of $1.024 billion versus $1.02 billion expected. CEO Al White highlighted growth in the MyDay portfolio and benefits from last year's reorganisation. The company develops and markets products for contact lens wearers through its CooperVision and CooperSurgical segments.